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Imipramine blue sensitively and 
selectively targets FLT3-ITD 
positive acute myeloid leukemia 
cells
Jonathan Metts1,2, Heath L. Bradley1,2, Zhengqi Wang1,2, Neil P. Shah3, Reuben Kapur4, Jack 
L. Arbiser5,6 & Kevin D. Bunting1,2
Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical 
growth and survival signals in high risk acute myeloid leukemia (AML). Inhibitors to FLT3 have already 
been tested in clinical trials, however, drug resistance limits clinical efficacy. Mutant receptor tyrosine 
kinases are mislocalized in the endoplasmic reticulum (ER) of AML and play an important role in 
the non-canonical activation of signal transducer and activator of transcription 5 (STAT5). Here, 
we have tested a potent new drug called imipramine blue (IB), which is a chimeric molecule with a 
dual mechanism of action. At 200–300 nM concentrations, IB is a potent inhibitor of STAT5 through 
liberation of endogenous phosphatase activity following NADPH oxidase (NOX) inhibition. However, 
at 75–150 nM concentrations, IB was highly effective at killing mutant FLT3-driven AML cells through a 
similar mechanism as thapsigargin (TG), involving increased cytosolic calcium. IB also potently inhibited 
survival of primary human FLT3/ITD+ AML cells compared to FLT3/ITDneg cells and spared normal 
umbilical cord blood cells. Therefore, IB functions through a mechanism involving vulnerability to 
dysregulated calcium metabolism and the combination of fusing a lipophilic amine to a NOX inhibiting 
dye shows promise for further pre-clinical development for targeting high risk AML.
Acute myeloid leukemia (AML), the most common leukemia in adults and second most common in pediatrics, is 
a heterogeneous disease with a high relapse rate. FLT3/ITD mutated AML represents 30% of adult and 10–20% of 
pediatric AML and despite intensive therapy and allogeneic stem cell transplant the prognosis for these patients 
remains dismal1, 2. FLT3/ITD mutations result in constitutive activation of key survival and growth pathways 
including STAT5, PI3K, and MAPK. Tyrosine kinase inhibitors (TKIs) that directly target FLT3 (e.g. sorafenib, 
quizartinib, etc) are currently being studied in clinical trials, however thus far they have produced modest 
responses, with TKI resistant mutations being a main cause of relapse3. Therefore, novel methods to target this 
high risk disease subset are warranted. Mislocalization of mutant type III receptor tyrosine kinases (RTKs, e.g. 
FLT3 and c-KIT) occurs in leukemia4, 5. In FLT3/ITD+ AML, a portion of mislocalized, underglycosylated RTK 
accumulates on the endoplasmic reticulum (ER) in a highly oxidized microenvironment where the RTK activates 
signal transducer and activator of transcription 5 (STAT5) through tyrosine phosphorylation, a phenomenon that 
does not occur with the mature fully glycosylated form, and there are high levels of localized reactive oxygen spe-
cies (ROS) generated from ER-bound NADPH Oxidase 4 (NOX4)4, 6. This non-canonical activation mechanism 
is leukemia-specific, thus opening the door to an improved therapeutic index for agents that are able to exploit 
this STAT5 activation mechanism.
ROS are highly reactive molecules containing oxygen. While typically produced by the mitochondria as a 
byproduct of cellular metabolism, in recent years ROS have been shown to play a key role in many aspects of cell 
signaling. ROS are elevated in AML and specifically AML with FLT3/ITD mutations7. NOX4 has been shown 
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to be a STAT5 target gene, and its upregulation in FLT3/ITD+ AML mediates leukemic transformation through 
inactivation of protein tyrosine phosphatases (PTPs) such as DEP-1 by causing reversible cysteine oxidation at 
their catalytic site. Furthermore, NOX4 inhibitors have been shown to increase survival in murine models of 
FLT3/ITD+ AML8. STAT5 is also directly affected by ROS; in FLT3/ITD+ AML cell lines, hydrogen peroxide 
(H2O2) co-localizes to the endoplasmic reticulum and is required for STAT5 phosphorylation9. These important 
roles of ROS in FLT3/ITD+ AML raise the possibility the ROS may be a therapeutic target for this disease.
Imipramine Blue (IB) is a triphenylmethane dye conjugated to the tricyclic antidepressant imipramine. Many 
effects of this compound have been discovered, however its most prominent effect is that of NOX inhibition10. 
IB has been shown to be effective in preclinical models of glioblastoma, Burkitt lymphoma, head and neck carci-
noma, breast cancer, and chronic myeloid leukemia (CML)10–14. Given the prominent role of NOX4 and ROS in 
FLT3/ITD+ AML, we sought to determine if FLT3/ITD+ AML might be preferentially sensitive to ROS inhibition. 
However, we uncovered a new mechanism of action where AML cells are also highly sensitive to cytosolic calcium 
(Ca2+) and vulnerable to Ca2+ overload induced mitochondrial cell death15, 16.
Materials and Methods
Cell culture. All cultured cell lines were grown in media containing 1% penicillin/streptomycin and found 
to be negative for mycoplasma contamination prior to use. The FLT3/ITD+ cell lines MV4–11, MOLM-13, and 
MOLM-14 were a gift from Doug Graham (Emory University). MV4–11 cells were grown in IMDM supple-
mented with 10% FBS, and MOLM-13 and MOLM-14 cells were grown in RPMI supplemented with 10% FBS. 
FLT3/ITDneg cell line OCI-AML3 was purchased from DSMZ and grown in αMEM supplemented with 10% 
FBS. FLT3/ITDneg cell lines HL-60, HEL, and K562 (blast crisis CML) were gifts from Gang Huang (Cincinnati 
Children’s Hospital) and William Tse (University of Louisville). HL-60 cells were grown in IMDM with 20% FBS 
and HEL and K562 cells were grown in RPMI + 10% FBS. MOLM-14 cells with acquired FLT3 point mutations17 
F691L (gatekeeper mutation) and D835Y (tyrosine kinase domain mutation) were grown in RPMI + 10% FBS. 
32D clone 3 cells transduced with wild-type c-KIT and c-KIT D814V mutation were grown in IMDM + 10% FBS 
supplemented with 5 ng/mL murine IL-3 (Gemini) and 32D KIT D814V cells were starved of IL-3 for at least 
24 hours prior to experimentation.
Human umbilical cord blood and primary patient samples. Umbilical cord blood units were 
obtained with IRB approval from the Carolinas Cord Blood Bank (Duke University). All methods were carried 
out in accordance with relevant guidelines and regulation. Informed consent was obtained for all subjects donat-
ing cord blood units to the bank. Mononuclear cells were extracted using Ficoll then counted via trypan blue to 
assess viability. CD34+ cells were then extracted utilizing the human UltraPure CD34 MicroBead Kit (Miltenyi, 
130-100-453). Cells were expanded as described18 in Stemspan H3000 serum free media (StemCell Technologies, 
#09800) supplemented with 100 ng/mL of human thrombopoietin, IL-6, FLT3 ligand, stem cell factor (Gemini) 
and 1 µM StemRegenin-1 (SR-1, Cayman Chemicals, #10625).
De-identified patient samples were obtained from the Children’s Oncology Group (COG) through the AML 
Biology Committee (AAML15B9-Q). Bone marrow samples containing 70% blasts or greater were from patients 
under 21 years of age at diagnosis prior to receiving any therapy. Samples were thawed and expanded in cytokines, 
SR-1, and UM-729 (StemCell, #72332) as described19. Samples were considered satisfactory quality for analysis if 
>50% viability was maintained after 5 days in culture.
Treatment reagents. Mitochondrial complex I inhibitors rotenone and metformin (#R8875 and # 
D150959), NOX inhibitor diphenyleneiodonium (DPI, #D2926), SERCA inhibitor thapsigargin (T9033), and 
STAT5 inhibitor pimozide (P1793) were purchased from Sigma. The lipophilic amine imipramine and the triphe-
nylmethane dyes gentian violet and imipramine blue were obtained from Sigma. Imipramine blue was prepared 
at PCI Synthesis, Newburyport, MA. PCI is a cGMP facility which has prepared imipramine blue, and confirms 
the identity of imipramine blue by mass spectroscopy and NMR spectroscopy.
Western blotting. Cells were lysed in RIPA buffer with protease and phosphatase inhibitors (Roche, 
#04693124001 and #04906845001) for 30 minutes on ice followed by centrifugation for 10 minutes at 10,000 × g. 
Protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad, # 500–0006) and proteins 
were separated on an SDS-polyacrylamide gel followed by transfer to either a nitrocellulose (Fisher, #1215471) or 
PVDF (Immobilon, #IPVH00010) membrane. After blocking in 5% BSA for 1 hour, membranes were incubated 
in the appropriate antibody overnight and detection was by chemiluminescence (Thermo Scientific, #34080) or 
by the Odyssey Clx imaging system (LI-COR Biosciences). Image Studio v4.0 software was used for densitometry 
quantification.
Assays of mitochondrial integrity. For ROS detection, cells were washed twice with PBS then incubated 
for 30 minutes in 1 µM H2-DCF-DA (Invitrogen, D-399) in PBS. After 2 more washes in PBS, hydrogen peroxide 
levels were detected by flow cytometry. For mitochondrial membrane potential, after 2 washes with PBS, cells 
were incubated with 5 µM JC-1 (Thermo-Fisher, T3168) in PBS for 20 minutes, then washed 3 times with PBS 
prior to analysis by flow cytometry20.
Cytoplasmic Calcium Assay. After 2 washes with serum-free RPMI medium, cells were incubated with 
serum-free RPMI with 5 µM Indo-1 AM (Thermo-Fisher, I1203) for 30 minutes. Cells were then washed 3 times 
with PBS. Flow cytometry was performed by ratiometric analysis of cytoplasmic calcium-bound vs unbound 
Indo-1 vs time. Analysis was performed for 30 seconds on untreated cells prior to the addition of treatment 
agents.
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Cell Imaging. The fluorescent properties of IB were utilized for localization analyses. IB is excited at 568 and 
emits fluorescence at >650. ER-tracker Green was purchased from Thermo-Fisher (E34250) and Golgi-ID and 
Lyso-ID were purchased from Enzo (ENZ-51028-K100 and ENZ-51034-0100). These dyes were chosen because 
they have no spectral overlap with IB. Hoechst stain provided in the Enzo kits was used for nuclear counterstain. 
Staining was performed according to manufacturer’s protocols. Cells were concurrently loaded with 150 nM IB. 
High resolution live-cell imaging was performed on the DeltaVision OMX (GE Healthcare). Post-acquisition data 
analysis was done using Fiji software (Fiji.sc).
Cell survival assays. For apoptosis assay, after 2 washes in PBS, cells were resuspended in Annexin Buffer 
with Annexin V-PE (BD Biosciences, 556421) and DAPI, according to the manufacturers’ instructions. Cells 
were analyzed by flow cytometry. For cytotoxicity assay, after 48 hours of drug treatments, cells were analyzed by 
trypan blue exclusion assay as previously described21.
Statistical Analysis. All data were derived as a result of three or more independent experiments, unless 
stated otherwise. Student’s two tailed t-test was used to calculate p-values and values less than 0.05 were consid-
ered to be significant.
Results
Inhibition of ROS potently inhibits STAT5 phosphorylation but induces cell death at lower con-
centrations. To determine the effects of ROS inhibition on STAT5 phosphorylation, we targeted the 2 main 
Figure 1. Imipramine blue selectively kills FLT3/ITD+ AML cell lines at lower concentrations than required 
to suppress STAT5 phosphorylation. (A) MV4–11 cells were treated with mitochondrial complex I inhibitors 
(rotenone and metformin) or NOX inhibitors (DPI and imipramine blue) for 4 hours prior to 30 minute H2-
DCF-DA staining and flow cytometry. For Western blots, MV4–11 cells were treated for 4 hours with or without 
1 mM PTP inhibitor sodium orthovanadate (Na3VO4). MitOX inhibitors decreased pSTAT5, and this effect was 
reversed in the presence of Na3VO4, indicating PTP liberation as the cause of decreased pSTAT5. (B) Trypan 
blue exclusion assay after 48 hours drug exposure. FLT3/ITD+ cell lines were selectively killed at nM doses of 
IB, specifically 100–150 nM. (C) Doses of 200 nM IB were required to see significant inhibition of pSTAT5. 
The original uncropped Western blot files are included as Supplemental material. (*p < 0.05, ***p < 0.001, 
****p < 0.0001, ns: p > 0.05).
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cellular ROS producers: mitochondria and NADPH oxidase. Utilizing mitochondria complex I (MitOX) inhibi-
tors (rotenone, metformin) and NADPH Oxidase (NOX) inhibitors (DPI, imipramine blue) for 4 hours, cellular 
levels of ROS as measured by hydrogen peroxide content in MV4–11 cells were effectively decreased. Western 
blot after 4 hour treatment demonstrated corresponding inhibition of pSTAT5 (Fig. 1A). Effective disruption of 
downstream STAT5 signaling was also observed using qRT-PCR for STAT5 target genes (Fig. S1). Co-treatment 
with 1 mM sodium orthovanadate (Na3VO4), a protein tyrosine phosphatase (PTP) inhibitor restored pSTAT5 
levels as measured by Western blot, implicating the liberation of PTPs by ROS inhibition as an effective method 
of pSTAT5 inhibition. (Fig.1A).
IB induces apoptosis that is selective for FLT3/ITD+ cell lines, alone and in combination with 
pimozide. Next we determined the effects of ROS inhibitors on AML cell death. With 48-hour drug treat-
ment, the MitOX inhibitors and the NOX inhibitor DPI did not show selectivity for FLT3/ITD+ cell lines 
(Fig. S2A–C). However, IB at 48 hours demonstrated potent and selective cell death for FLT3/ITD+ cell lines 
tested, with relatively little effect on FLT3/ITDneg lines (Fig. 1B) Surprisingly, the IC50 values for the FLT3/ITD+ 
cell lines were between 100–150 nM, below the dose of IB where pSTAT5 inhibition was achieved (Fig. 1C). 
Therefore, we hypothesized that the mechanism of cell death was independent of direct FLT3/ITD/pSTAT5 inhi-
bition and AML which becomes resistant to TKIs may remain sensitive to IB. We tested MOLM-14 cells which 
were transduced with acquired FLT3 point mutations that occur clinically and confer TKI resistance. Cell lines 
with these point mutations demonstrated resistance to the highly specific FLT3 inhibitor AC-220, but conferred 
no resistance to IB. (Fig. 2A,B).
To optimize selectivity and FLT3/ITD+ cytotoxicity, we also combined IB with the STAT5 inhibitor pimozide, 
which inhibits pSTAT5 at doses ≥5 µM in the MV4–11 cell line (Fig. 2C)22, 23. Doses that were suboptimal for killing 
FLT3/ITD+ cell lines at 48 hours were surprisingly selective and synergistic for FLT3/ITD+ cell lines, sparing FLT3/
ITD negative cell lines and CD34+ cord blood cells (Fig. 2D,E). The combination was also selective and synergistic 
for 32D cells transduced with c-KIT D814V mutant when compared to 32D cells with wild-type c-KIT (Fig. 2F).
We next determined the role of apoptosis in IB cytotoxicity. Annexin V/DAPI staining after 18 hours of drug 
treatment caused significant increases in the Annexin single positive and Annexin/DAPI double positive popula-
tions in MV4–11 cells with little effect on OCI-AML3 cells, indicating a selective cell death through apoptosis in 
Figure 2. Imipramine blue targets AC220-resistant FLT3/ITD mutants and synergizes with pimozide to 
selectively kill FLT3/ITD and KIT/D814V expressing cells. (A and B) By trypan blue exclusion assay at 48 hours 
of drug treatment, MOLM-14 cells with acquired point mutations in the tyrosine kinase domain (D835Y) and 
gatekeeper domain (F691L) were resistant to AC-220, but demonstrated no resistance to IB as compared to the 
parental MOLM-14 line. (C) Pimozide inhibited pSTAT5 at μM doses in MV4–11 cells. (D and E) Trypan blue 
exclusion assay at 48 hours showed that in combination, sub-optimal doses of IB and pimozide were highly 
synergistic and selective in FLT3/ITD+ cell lines, including those with FLT3 point mutations, with little effect on 
FLT3/ITDneg cell lines or on CD34+ cord blood cells. (F) 32D cells transduced with c-KIT D814V mutation were 
also sensitive to IB/Pimozide. The original uncropped Western blot files are included as Supplemental material. 
(*p < 0.05, ****p < 0.0001, ns: p > 0.05).
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the FLT3/ITD+ cell line (Fig. 3A). This was confirmed by significantly increased cleavage of Caspase 3 in MV4–11 
cells treated for 24 hours (Fig. 3B).
IB co-localizes to lysosomes and causes cytosolic Ca2+ release. Given the properties of IB as a lipo-
philic amine moiety conjugated to a triphenylmethane dye, we next hypothesized that cellular organelles may 
have disproportionately higher uptake of IB, leading to organelle stress (Fig. 4A). To determine if a specific orga-
nelle is targeted by IB, we utilized the fluorescent properties for cellular imaging. Organelle tracking dyes were 
used to determine cellular localization of organelles with substantial Ca2+ stores: ER, Golgi complex, and lyso-
somes. We found IB to localize outside of the nucleus in a punctate pattern. On dual ER/IB localization, we noted 
that IB localized to the same region of cells, but did not overlap with the ER or the Golgi (Fig. 4B). However there 
was a high degree of co-localization observed with lysosomes. This is consistent with the previously described 
phenomenon of “lysosomal trapping” of lipophilic amines due to the acidic environment of the lysosome24.
We next evaluated the effects of IB on cytosolic calcium release utilizing the Indo-1 assay. IB induced Ca2+ 
release in MV4–11 cells as did the positive control thapsigargin (TG), a SERCA inhibitor which blocks Ca2+ reup-
take by the ER and Golgi complex (Fig. 4C). Gentian violet, a triphenylmethane dye without a conjugated amine 
did not induce Ca2+ release, nor did the IB pro-drug imipramine, demonstrating that this is a unique characteris-
tic of IB (Fig. 4C). IB also induced calcium release in OCI-AML3 cells, indicating this is not a FLT3/ITD-specific 
phenomenon (Fig. 5A). However, the peak Indo-1 bound/unbound ratio for OCI-AML3 cells was not as remark-
able as for MV4–11 cells, indicating that the Ca2+ release may be more dramatic in FLT3/ITD+ cells. Ca2+ release 
and overload of the mitochondria is known to induce a loss of mitochondrial membrane potential (ΔΨm) and 
apoptosis. We then treated cell lines for 48 hours with TG and saw a similar sensitive and selective cytotoxicity for 
FLT3/ITD+ cell lines, confirming the role of cytoplasmic Ca2+ (Fig. 5B). We therefore examined the effects of IB 
Figure 3. Imipramine blue targets FLT3/ITD+ AML cells by inducing caspase 3 cleavage and apoptosis. (A) 
After 18 hours of drug treatment, Annexin V/DAPI assay demonstrated a population of Annexin V+/DAPIneg 
and a population of Annexin V+/DAPI+ cells that was statistically significant for MV4–11 cells but not for OCI-
AML3, indicating the IB was selectively inducing cell death through apoptosis (B) Western blot after 24 hours 
of drug treatment in MV4–11 cells demonstrated significant Caspase 3 cleavage at doses of 100 and 150 nM IB, 
indicating induction of apoptosis as a mechanism of IB-mediated cell death. The original uncropped Western 
blot files are included as Supplemental material. (*p < 0.05, ***p < 0.001, ns: p > 0.05).
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and TG on ΔΨm. Both IB and TG caused an increase in JC-1 monomers, indicating that Ca2+ release is causing 
a loss of mitochondrial membrane potential, resulting in mitochondria-induced (intrinsic) apoptosis (Fig. 5C).
FLT3/ITD+ patient samples are more sensitive to IB than FLT3/ITDneg samples. Utilizing primary 
pediatric AML samples obtained at the time of diagnosis in de novo AML patients, we next determined the effects 
of IB treatment. Annexin V flow assay demonstrated a larger population of Annexin V+/DAPIneg cells at 18 hours 
of 150 nM IB treatment that trended toward statistical significance (p = 0.06). FLT3/ITDneg samples remained rel-
atively unaffected (Fig. 6A). At 48 hours post-treatment, trypan blue assay showed that FLT3/ITD+ samples were 
sensitive to IB in similar doses to FLT3/ITD+ cell lines while FLT3/ITDneg samples were not, demonstrating that 
IB effectively targets more heterogeneous populations of primary FLT3/ITD+ AML cells (Fig. 6B).
Discussion
AML with the FLT3/ITD mutation portends a poor prognosis. The mutation alone is insufficient to generate 
an acute leukemic transformation but induces myelo- and lymphoproliferative disease and FLT3/ITD has been 
validated as a therapeutic target17, 25, 26. Both multikinase (e.g. sorafenib) and more selective class III receptor 
tyrosine kinase inhibitors (TKIs) (e.g. quizartinib) have now reached early-phase clinical trials, however durable 
remissions with TKI monotherapy have been limited. Multiple mechanisms are responsible for acquired TKI 
resistance, with the most prominent being the acquisition or expansion of AML clones with the ITD as well as 
TKD point mutations27. Current translational and clinical efforts targeting FLT3/ITD expressing cells include the 
development of more robust TKIs (e.g. crenolanib) and utilization of TKIs in combination with chemotherapy 
backbones or following hematopoietic stem cell transplantation as a maintenance therapy28. Given the numerous 
proliferative and anti-apoptotic downstream pathways activated by FLT3/ITD (STAT5, PI3K, MAPK), targeting 
of downstream lesions is an attractive alternative to direct inhibition of FLT3/ITD.
The data presented here reveals that the NOX inhibitor IB induces a potent and selective cell death to FLT3/
ITD+ AML through dual mechanisms of ROS/STAT5 inhibition as well as lysosomal Ca2+ release. Through the 
Figure 4. Imipramine blue is trapped in the lysosomes and increases cytosolic calcium concentration 
comparable to thapsigargin. (A) Molecular structure of IB, demonstrating the conjugation of Imipramine to a 
triphenylmethane dye. (B) (Representative result) Live cell imaging of organelle trackers and IB demonstrated 
a co-localization of 150 nM IB with lysosomal tracker, which was not seen with ER and Golgi tracker. (C) 
(Representative result) IB and the SERCA inhibitor TG caused a surge in cytoplasmic Ca2+ while Imipramine 
and Gentian Violet showed minimal effect on Ca2+ release.
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decreased production of NOX-derived ROS, IB potently inhibits the tyrosine phosphorylation and activation of 
STAT5 at doses of approximately 200–300 nM. Surprisingly, IB was highly selective against FLT3/ITD+ AML at 
75–150 nM doses, which induced cytosolic Ca2+ release from lysosomes, resulting in mitochondrial outer mem-
brane permeabilization, caspase activation, and intrinsic apoptosis29. The therapeutic strategy of cytosolic Ca2+ 
release was confirmed through SERCA inhibition with TG, which also resulted in potent and selective cell death 
of FLT3/ITD+ cells. Ca2+ release may occur via the inhibition of calcium re-uptake channels (e.g. SERCA inhib-
itors) or through the disruption of Ca2+-storing organelles (i.e. the endoplasmic reticulum; ER, Golgi apparatus, 
and lysosomes)30, 31. We also discovered a novel synergistic combination of IB with the STAT5 inhibitor pimozide 
which effectively targets FLT3/ITD+ AML while sparing cell lines without the mutation and sparing CD34+ cord 
blood cells. Importantly for IB monotherapy and the IB/pimozide combination, no drug resistance was observed 
for FLT3/ITD+ cell lines with acquired TKD mutations, indicating that IB and IB/pimozide may be able to over-
come this substantial hurdle to FLT3/ITD+ AML treatment. IB also effectively induced cytotoxicity in FLT3/ITD+ 
primary patient samples, indicating this therapeutic strategy has potential in more heterogeneous leukemic cell 
populations. The dual-effects of IB cytotoxicity and the synergistic combination of IB/pimozide are attractive 
therapeutic strategies because of their selectivity for FLT3/ITD mutations, and there is likely less potential for 
development of drug resistance.
STAT5, a crucial transcription factor for hematopoiesis, is activated through tyrosine phosphorylation. Because 
of its broad roles in hematopoiesis and hematopoietic stem cells (HSCs), our lab and others have shown that dele-
tion of STAT5 causes significant immune suppression, multilineage cytopenias, and stem cell dysfunction, thus 
far limiting the feasibility of STAT5 as a druggable target. STAT5 is classically activated through the canonical 
JAK-STAT pathway. However, STAT5 activation can be uncoupled from canonical JAK2-STAT5 activation32. Its 
downstream targets include several anti-apoptotic and pro-survival genes (i.e. c-Myc, Pim-1, etc) that are known 
to be associated with oncogenic transformation33. STAT5 is downstream of many oncogenic tyrosine kinases 
including FLT3/ITD, BCR-ABL, JAK2V617F, KITD816V and others, making it an attractive target for anti-leukemic 
therapy34. Unfortunately, STAT5 inhibition as a therapeutic target has been difficult to achieve and there is lack 
of preclinical and clinical agents with the capability to directly target STAT5, although there are now some new 
compounds with advantages and some limitations35–37. Typically STAT5 inhibition occurs through the inhibition 
of upstream tyrosine kinase pathways and inhibitors to FLT3, JAKs, and BCR-ABL may lead to drug resistance.
Figure 5. Low dose imipramine blue-mediated calcium induced cell death and both imipramine blue and 
thapsigargin are potent inducers of mitochondrial outer membrane permeabilization. (A) (Representative result 
of n = 3) Indo-1 cytoplasmic Ca2+ assay. IB and TG caused Ca2+ release in OCI-AML3 cells to a lesser extent 
(a,b). In MV4–11 cells, IB and TG demonstrated an influx of cytoplasmic Ca2+ that was reversed by the addition 
of 5 μM BAPTA (c, d) (B) Trypan blue exclusion assay after 48 hours of drug treatment showed that TG has a 
similar selective cytotoxicity profile as IB for FLT3/ITD+ cell lines, implicating Ca2+ release in the mechanism 
of cell death. (C) JC-1 assay demonstrated a significant increase in JC-1 monomers after 18 hours of drug 
treatment with IB or TG in MV4–11 cells. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: p > 0.05).
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 4447  | DOI:10.1038/s41598-017-04796-1
ROS was historically considered an unwanted by-product of cellular metabolism, however recent work has 
demonstrated several important roles of ROS as a cell signaling mediator and also roles in oncogenesis, including 
in AML38, 39. FLT3/ITD+ AML has increased ROS through several mechanisms including the stabilization expres-
sion of the NOX subunit p22phox, increased expression of NOX4, and binding of Rac1-GTP to STAT57, 8, 40. One 
important role is the inactivation of PTPs through reversible oxidation of cysteines leading to the formation of 
disulfide bridges and inactivation of the enzyme41. As demonstrated here, IB treatment can restore PTP activity 
through inhibition of ROS leading to decreased tyrosine-phosphorylated STAT5 at nanoMolar doses. This may 
serve as an attractive STAT5 inhibitor not only for FLT3/ITD+ AML but more broadly for other leukemia and 
myeloproliferative neoplasms with constitutive STAT5 activation to be tested in future studies. Furthermore the 
combination of ROS inhibition with pimozide conferred a synergistic cell death at sub-therapeutic doses of each 
drug, demonstrating a potentially useful combination therapy.
Like ROS, Ca2+ is also an important mediator of cell signaling. There exists an intimate interconnection of 
Ca2+-containing organelles including endoplasmic reticulum, lysosomes, Golgi, and mitochondria. The ER and 
mitochondria have multiple contact sites that allow transfer of Ca2+. Ca2+ release at high doses from the ER to 
mitochondria may trigger apoptosis through mitochondrial swelling, cytochrome C release, caspase cleavage 
and mitochondrial rupture. Importantly, lysosomes have recently been identified as an intracellular Ca2+ store42. 
Lysosomal Ca2+ efflux may also cause a robust release of Ca2+ from the ER, likely through the activation of IP3 
and ryanodine receptors on the ER43, 44. This may explain the robust Ca2+ release caused by IB, which is similar 
in intensity to that of the SERCA inhibitor thapsigargin. Peshakov et al. confirmed a selective cytotoxic and 
anti-proliferative effect of Ca2+ overload and caspase-induced apoptosis in AML cells using a combination of 
curcumin and carnosic acid, however the authors did not test AML cells with the FLT3/ITD mutation, so it is 
unknown if this strategy has greater effects on that subset of AML45.
There are important implications regarding the underlying mechanism of IB-induced FLT3/ITD+ AML cell 
death that remain to be determined. It is unclear at this time why IB would preferentially target the lysosome, 
however we hypothesize that this is due to “lysosomal sequestration”, in which hydrophobic amines such as imi-
pramine accumulate in highly acidic environments (i.e. lysosomes) where they become protonated and are una-
ble to diffuse out of the organelle46. This mechanism would not be specific to FLT3-ITD+ AML cells. If this is 
true, then IB must possess a unique property to induce lysosomal Ca2+ release as compared to its pro-drug 
imipramine, which did not induce a cytoplasmic Ca2+ release in our experiments. Another important issue is 
the question of IB’s selectivity for FLT3/ITD+ cells. One possibility is that mitochondria are more sensitive to 
Ca2+ overload compared to FLT3/ITDneg AML cells. In addition to STAT5 inhibition, pimozide, a neuroleptic 
agent, also induces multiple metabolic perturbations including blocking T-type calcium channels which may be 
Figure 6. Imipramine blue is an effective inducer of apoptosis and selective killing of primary human FLT3/
ITD+ AML cells compared with FLT3/ITDneg AML cells. (A) After 18 hours treatment with 150 nM IB, FLT3/
ITD+ samples demonstrate apoptosis by Annexin V single positive staining, which was not seen in FLT3/ITDneg 
samples. (B) 48 hour trypan blue exclusion assay showed sensitivity to IB for FLT3/ITD+ at similar doses to 
cell lines. (C) Two-fold dose-dependent mechanism for IB-induced FLT3/ITD+ AML cell death. (*p < 0.05, 
**p < 0.01, ns: p > 0.05).
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responsible for synergy with IB. T-type calcium channels can alter cell cycle dynamics through the action poten-
tial generated by a calcium spike. When ER calcium release is accelerated by IB treatment, this hyperpolarization 
would normally be associated with relieved inactivation of T-type channels. However, pharmacologic inactivation 
of T-type channels with pimozide could prevent cell proliferation that would normally proceed through calcium 
mediated p53 inactivation, activation of p21, and release of CDK2 to promote S phase transition. Finally, a safe 
and efficacious in vivo therapeutic approach is needed. Ca2+ release as a therapeutic target is currently being 
tested by using a pro-drug of the SERCA inhibitor thapsigargin (mipsagargin, G-202) in clinical trials for prostate 
cancer and hepatocellular carcinoma47. In this study, we have demonstrated that the imipramine/triphenylmeth-
ane conjugate agent imipramine blue possess potent and selective cytotoxic effects alone and in combination with 
pimozide for FLT3/ITD+ AML. The potential clinical utility of this combination remains to be determined. IB 
acts through a dual mechanism involving STAT5 inhibition and lysosomal Ca2+ release at nM concentrations. 
IB thus represents an exciting new agent and chimeric prototype drug with promise for future development in 
treating high risk subsets of AML.
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